Dr. Aldrich conducts cutting-edge research to inform the prevention, diagnosis, and treatment of lung cancer for all populations. Her work encompasses two primary areas of focus: 1) understanding genetic and non-genetic determinants of health contributing to lung cancer risk and outcomes in underrepresented populations, and 2) addressing inequities in lung cancer screening. As a leader in lung cancer screening research, her work has played a pivotal role in shaping key health policy guidelines for lung cancer screening issued by the U.S. Preventive Services Task Force (USPSTF).

Collaborative scientific efforts are underway with national colleagues to investigate the genetics of immunotherapy treatment among lung cancer patients, to assess the impact of structural racism on lung cancer inequities, to identify barriers and facilitators to the recruitment of underrepresented populations to lung cancer clinical trials and to construct residential histories to investigate area-level risk factors among populations experiencing disparities. Additional ongoing research is investigating the population genetics of admixed African ancestry populations. Dr. Aldrich also leads a lung cancer focused community advisory board to spearhead community-engaged dissemination strategies addressing inequities in the early detection of lung cancer.